Vicore Pharma Holding AB American Depositary Shares
Market Cap
320M
Short interest (Jul 15)
0.0%
Net Short (Jul 27 ): 0.0%
Borrow Fee
19.86%
↓ 16.3%
Available Shares
20K
↑ 172.7%
Price Chart
Company Overview
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.